FDA Approves FERAHEME — AMAG Pharmaceuticals, Inc

# FDA Approves AMAG Pharmaceuticals' FERAHEME for Iron Deficiency Treatment AMAG Pharmaceuticals, Inc. received FDA approval for FERAHEME (ferumoxytol), an intravenous iron replacement therapy, positioning the company to capture market share in the estimated $2+ billion iron deficiency treatment market, particularly among patients with chronic kidney disease who require rapid iron replenishment. The approval of this novel ferumoxytol formulation expands AMAG's product portfolio and establishes a competitive foothold against existing iron replacement therapies.